Celularity Inc (CELU) Stock Price, Quote & News

Company Profile

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 768 2170

Website: www.celularity.com

Address:

170 Park Avenue, Florham Park, United States

FunCoupons00 Oct. 24 at 12:42 PM

$QBTS just a little caveat people may not realize, Peter Diamandis from $QBTS is also the co-founder of $CELU so when this is 10x-20x just Remeber to follow the money & not kick yourself when this is a $25 stock overnight

1 · Reply

Nosay Oct. 23 at 7:40 PM

$CELU confident to say now that this was someone covering their short. About the same amount disappeared from the short amount between Sept 15 and 30th.

2 · Reply

luckydog2 Oct. 23 at 3:58 PM

$CELU The feedback on Biovance is incredible. Outstanding results and less time spent in the OR. Great news for doctors and patients. https://www.reddit.com/r/CelularityNews/s/MVG7xCLoT7

0 · Reply

CharlieMungersghost Oct. 22 at 12:13 PM

$CELU wen earnings ?

2 · Reply

KingStocks1 Oct. 21 at 4:08 AM

$CELU dead

0 · Reply

GreatGP Oct. 21 at 3:50 AM

$CELU a lot going on here, new science, small market cap, CEO getting promotional

0 · Reply

zvac Oct. 17 at 3:58 PM

$CELU

1 · Reply

luckydog2 Oct. 17 at 3:26 PM

$CELU Defeye CEO Rob Sambursky, MD on Biovance and new product Interfyl. https://www.reddit.com/r/CelularityNews/s/RXfzFkmAhd

0 · Reply

Adam_85 Oct. 17 at 11:06 AM

$CELU Where all my Bulls at?

1 · Reply

Adam_85 Oct. 16 at 11:06 AM

$CELU can we see a push to $3+ today?

0 · Reply

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

Sep 3, 2025, 8:00 AM EDT - 7 weeks ago

Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance

Aug 22, 2025, 5:30 PM EDT - 2 months ago

Celularity Receives Nasdaq Notice Regarding Form 10-Q

Aug 18, 2025, 8:00 AM EDT - 2 months ago

Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt

Jul 9, 2025, 8:30 AM EDT - 3 months ago

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

Jul 1, 2025, 8:30 AM EDT - 4 months ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

Jun 10, 2025, 4:15 PM EDT - 4 months ago

Celularity Announces Chief Financial Officer Transition

Jun 2, 2025, 8:00 AM EDT - 5 months ago

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology

May 9, 2025, 9:15 AM EDT - 6 months ago

Celularity Announces Full Year 2024 Operating and Financial Results

Apr 25, 2025, 5:30 PM EDT - 6 months ago

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees

Apr 14, 2025, 8:00 AM EDT - 6 months ago

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products

Feb 25, 2025, 8:00 AM EST - 8 months ago

Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products

Feb 24, 2025, 8:00 AM EST - 8 months ago

Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company

Dec 10, 2024, 8:00 AM EST - 11 months ago

Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter

Dec 6, 2024, 8:00 AM EST - 11 months ago

Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023

Nov 27, 2024, 5:00 PM EST - 11 months ago

Celularity Inc. Announces Receipt of Nasdaq Notification

Nov 20, 2024, 8:30 AM EST - 1 year ago

Celularity's Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific

Oct 23, 2024, 8:30 AM EDT - 1 year ago

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Oct 18, 2024, 6:00 PM EDT - 1 year ago

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Oct 16, 2024, 5:15 PM EDT - 1 year ago

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Sep 5, 2024, 4:05 PM EDT - 1 year ago

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Aug 28, 2024, 4:45 PM EDT - 1 year ago

Celularity Appoints Richard J. Berman to its Board of Directors

Aug 23, 2024, 5:00 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Jun 3, 2024, 8:38 AM EDT - 1 year ago

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 14, 2024, 9:15 AM EDT - 1 year ago

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Celularity Inc. to Host Investor and Analyst Research & Development Day

Apr 19, 2024, 5:30 PM EDT - 1 year ago

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Apr 18, 2024, 4:30 PM EDT - 1 year ago

Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Apr 8, 2024, 9:00 AM EDT - 1 year ago

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells

Mar 26, 2024, 9:00 AM EDT - 1 year ago

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L

Mar 20, 2024, 9:15 AM EDT - 1 year ago

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Mar 14, 2024, 9:15 AM EDT - 1 year ago

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

Mar 12, 2024, 9:20 AM EDT - 1 year ago

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

Mar 7, 2024, 9:35 AM EST - 1 year ago

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells

Feb 23, 2024, 4:10 PM EST - 1 year ago

Celularity Announces 1-for-10 Reverse Stock Split

Feb 14, 2024, 4:05 PM EST - 1 year ago

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Feb 1, 2024, 9:00 AM EST - 1 year ago

Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline

Jan 25, 2024, 9:00 AM EST - 1 year ago

Celularity and Genting Leaders Comments on Closing $21 Million Financing Transactions

Jan 18, 2024, 1:40 PM EST - 1 year ago

Celularity Releases CEO Letter to Shareholders

Jan 4, 2024, 1:00 PM EST - 1 year ago

Celularity Confirms Commercialization Agreement with BioCellgraft for the Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Jan 3, 2024, 12:00 PM EST - 1 year ago

Celularity Announces Net Sales and Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023

Oct 18, 2023, 9:00 AM EDT - 2 years ago

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

Sep 7, 2023, 4:10 PM EDT - 2 years ago

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

Aug 29, 2023, 9:00 AM EDT - 2 years ago

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

Jul 27, 2023, 9:07 AM EDT - 2 years ago

Celularity Inc. Announces $3 Million Registered Direct Offering

Jul 27, 2023, 9:00 AM EDT - 2 years ago

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

Jul 18, 2023, 9:00 AM EDT - 2 years ago

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

FunCoupons00 Oct. 24 at 12:42 PM

1 · Reply

Nosay Oct. 23 at 7:40 PM

$CELU confident to say now that this was someone covering their short. About the same amount disappeared from the short amount between Sept 15 and 30th.

2 · Reply

luckydog2 Oct. 23 at 3:58 PM

$CELU The feedback on Biovance is incredible. Outstanding results and less time spent in the OR. Great news for doctors and patients. https://www.reddit.com/r/CelularityNews/s/MVG7xCLoT7

0 · Reply

CharlieMungersghost Oct. 22 at 12:13 PM

$CELU wen earnings ?

2 · Reply

KingStocks1 Oct. 21 at 4:08 AM

$CELU dead

0 · Reply

GreatGP Oct. 21 at 3:50 AM

$CELU a lot going on here, new science, small market cap, CEO getting promotional

0 · Reply

zvac Oct. 17 at 3:58 PM

$CELU

1 · Reply

luckydog2 Oct. 17 at 3:26 PM

$CELU Defeye CEO Rob Sambursky, MD on Biovance and new product Interfyl. https://www.reddit.com/r/CelularityNews/s/RXfzFkmAhd

0 · Reply

Adam_85 Oct. 17 at 11:06 AM

$CELU Where all my Bulls at?

1 · Reply

Adam_85 Oct. 16 at 11:06 AM

$CELU can we see a push to $3+ today?

0 · Reply

sumdumguy2 Oct. 15 at 11:03 PM

$CELU no cash, horrible burn rate. other than an interesting chart this thing is fugly.

0 · Reply

ERQ Oct. 15 at 7:09 PM

$CELU

0 · Reply

KingStocks1 Oct. 15 at 5:40 PM

$CELU this shit is dead

0 · Reply

Adam_85 Oct. 15 at 1:33 PM

$CELU !!!

0 · Reply

luckydog2 Oct. 15 at 12:47 PM

$CELU Robert Hariri: "I will lead a 'longevity revolution' with placental stem cells"… Presenting a vision for reverse aging. https://www.reddit.com/r/CelularityNews/s/SkY2sgOoHP

1 · Reply

Adam_85 Oct. 15 at 11:02 AM

$CELU Lets get after it Bulls

0 · Reply

OvercomingFears Oct. 15 at 2:03 AM

Make sure to have ticker GIPR on watch for tomorrow! That strong close is a signal—buyers aren’t done yet on GIPR. The setup is tight, momentum is building, and shorts look exposed. This could squeeze hard and take out $4.X+ quickly. Don't be late on GIPR bulls it's a beautiful setup. $SXTP $TROX $OBIO $CELU ..6

0 · Reply

ERQ Oct. 14 at 11:03 PM

$CELU That was great news today! glad to see they are moving things along. I got a feeling they also are about to drop one of the 510k submissions soon.

1 · Reply

Andy_mc Oct. 14 at 9:43 PM

$CELU The way this stock price moves is absolutely terrifying! It's been 4 years that I've been trading CELU and it's been a love/hate relationship :L

0 · Reply

Dtradeyou1 Oct. 14 at 7:55 PM

$CELU Don't short on margin.

0 · Reply

_www_larval_com_ Oct. 14 at 4:37 PM

$CELU just soared 4% higher to 9% (~2Mv) a moment ago, 10/17 options, follow for more volatility.

0 · Reply

Adam_85 Oct. 14 at 3:25 PM

$CELU Let's go Bulls keep up the pressure. I would love to see $3+ today.

1 · Reply

Market Cap	53.12M
Revenue (ttm)	54.22M
Net Income (ttm)	-57.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-106.77%
Debt to Equity Ratio	-1.70

Volume	72,500
Avg Vol	168,098
Day's Range	N/A - N/A
Shares Out	26.69M
Stochastic %K	33%
Beta	0.75
Analysts	Sell
Price Target	$6.00